Skip to main content

Advertisement

Table 4 Patient characteristics associated with meeting the TM and the CAM

From: Clinical action measures improve the reliability of feedback on quality of care in diabetes centres: a retrospective cohort study

Diabetes type T1 T2
Meeting the measure TM–CAM− TM–CAM + TM + CAM + TM–CAM− TM-CAM + TM + CAM +
A. LDL cholesterol
 n 196 30 342 347 62 696
 Age (years), mean 48 51 51 * 69 71 69
 Diabetes duration (years), mean 20 20 22 17 17 18
 Time before start insulin therapy (years), mean 0.2 0.3 0.5 7.8 8.2 8.6
 Duration insulin therapy (years), mean 20 20 21 9.2 8.4 9.2
 Smoking status (%)
  Never smoked 63.7 50.0 65.8 65.6 59.3 66.9
  Ex-smoker 13.5 23.3 12.7 25.0 28.8 24.2
  Smoker 22.8 26.7 21.5 9.4 11.9 8.9
 Presence of complication (%)
  CV_hist1 (° for T2D) 8.7 10.0 4.1 40.9 38.7 15.5
  CV_hist2 (° for T1D, ° for T2D) 13.8 16.7 4.4 48.4 50.0 18.7
  CV_hist3 ($ for T1D, ° for T2D) 15.4 18.5 6.2 52.4 55.2 24.2
  Microvascular complication 51.6 60.9 53.8 71.7 81.8 73.2
  Absent foot pulses or abnormal sensitivity 14.2 16.0 16.0 36.3 43.1 33.5
 Treated with (%)
  Antiplatelet drugs (* for T1D) 29.1 50.0 36.9 71.6 69.4 74.5
  Lipid-lowering drugs ($ for T1D, $ for T2D) 32.6 93.3 50.9 71.5 93.5 83.5
  Antihypertensive drugs 40.8 46.7 51.0 86.4 87.1 87.0
  Oral antidiabetic drugs (° for T2D) 7.7 13.3 8.9 51.3 33.9 58.4
B. non-HDL cholesterol
 n 315 49 870 713 125 1349
 Age (years), mean 47 49 50 $ 69 70 70
 Diabetes duration (years), mean 19 21 22 $ 17 17 18
 Time before start insulin therapy (years), mean 0.2 0.4 0.3 7.9 7.5 8.0
 Duration insulin therapy (years), mean 18 21 22 ° 8.9 8.7 9.5
 Smoking status (%)
  Never smoked 57.2 61.7 65.0 60.5 60.4 65.0
  Ex-smoker 15.1 19.1 14.9 27.8 29.7 25.2
  Smoker 27.6 19.1 20.0 11.7 9.9 9.8
 Presence of complication (%)
  CV_hist1 (° for T1D, ° for T2D) 9.5 8.2 4.0 37.5 40.3 17.4
  CV_hist2 (° for T1D, ° for T2D) 12.4 10.2 5.3 45.7 55.2 21.1
  CV_hist3 ($ for T1D, ° for T2D) 13.9 14.6 7.8 50.1 60.3 27.0
  Microvascular complication (* for T2D) 52.1 73.0 53.8 74.7 85.3 73.9
  Absent foot pulses or abnormal sensitivity (* for T2D) 12.0 15.4 14.8 37.0 43.3 32.4
 Treated with (%)
  Antiplatelet drugs ($ for T1D) 22.2 36.7 33.0 72.1 69.6 72.4
  Lipid-lowering drugs (° for T1D, ° for T2D) 29.5 98.0 45.2 69.1 95.2 81.9
  Antihypertensive drugs ($ for T1D) 35.9 44.9 45.8 84.9 83.9 86.2
  Oral antidiabetic drugs ($ for T2D) 8.0 8.2 8.4 53.7 41.9 56.4
  1. Patient characteristics that were associated with meeting the TM and the CAM based on LDL cholesterol (Table 4a) and non-HDL cholesterol (Table 4b). Mean age, diabetes duration, time before start insulin therapy and duration of insulin therapy is compared between the population neither meeting the TM nor the CAM (TM-CAM-), those not meeting the TM but meeting the CAM (TM-CAM+) and those meeting the TM and the CAM (TM + CAM+). Statistical significance between means was tested with the Pairwise Wilcox test, Holm adjustment: p < 0.001(°), p < 0.01 ($) and p < 0.05 (*) vs. not meeting the TM or the CAM (TM-CAM-). The proportion of patients with a complication, treated with drugs, and the distribution of smoking status is compared between the population neither meeting the TM nor the CAM (TM-CAM-), those not meeting the TM but meeting the CAM (TM-CAM+) and those meeting the TM and the CAM (TM + CAM+). Statistical significance between percentages was tested with the χ2-test: p < 0.001 (°), p < 0.01 ($) and p < 0.05 (*)